



Enterome to Present at Upcoming Conferences

Paris, France – April 7, 2021

ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health, today announces that Pierre Bélichard, CEO, will present an overview of the Company and take part in 1-on-1 meetings with institutional investors at the following conferences:

- European Biotech Investor Days: April 7-8
- Jefferies Microbiome-based therapeutics Summit: April 22
- Jefferies Virtual Healthcare Conference: June 1-3

Enterome's CBO, Anne Dagallier, will participate and take part in 1-on-1 meetings with potential business partners at the following conferences:

- Digestive Disease Week (DDW): May 21-23
- BIO International Convention: June 14-18

Contacts

Enterome

MARINE PERRIER
Head of External Communications
and Investor Relations
investorrelations@enterome.com

Media Relations

MARK SWALLOW / SYLVIE BERREBI / DAVID DIBLE
Citigate Dewe Rogerson
Tel. +44 207 638 9571
enterome@citigatedewerogerson.com

About Enterome

Enterome is a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health. Enterome's success is based on its unique ability to identify small proteins and peptides ("effectors") from gut bacteria that can deliver a therapeutic benefit in humans.



Enterome is leveraging this unique ability to develop two highly promising pipelines of clinical and pre-clinical candidates with a focus on cancer, inflammatory and metabolic diseases:

- **OncoMimics:** highly effective, off-the-shelf immunotherapies against cancers (EO2401, EO2463). EO2401 is in Phase 1/2 clinical trials in patients with glioblastoma and adrenal tumors. EO2463, is about to enter clinical development for indolent non-Hodgkin B-cell lymphomas.
- **EndoMimics:** a new generation of biologics targeting inflammatory diseases (EM101) and metabolic diseases such as Type 2 diabetes.

These pipelines have been created using Enterome's highly efficient proprietary drug discovery platform that uses machine learning and lab assays to interrogate and decode the world's largest database of gut bacterial proteins, a unique source of novel precision drugs.

In addition, Enterome's clinical candidate Sibofimloc (also referred to as TAK-018) is advancing through Phase 2 clinical trials in Crohn's disease. Sibofimloc has been partnered with Takeda globally, with Enterome retaining a significant profit share in the US.

Enterome is headquartered in Paris (France) and is backed by leading venture capital investors.

For more information, please visit the company's website at: www.enterome.com.